Methoxyetomidate hydrochloride - Shanghai Fosun Pharmaceutical
Alternative Names: ET-26Latest Information Update: 26 Dec 2023
At a glance
- Originator Shanghai Fosun Pharmaceutical
- Developer Ahon Pharmaceutical
- Class Benzene derivatives; Carboxylic acids; Ethers; General anaesthetics; Imidazoles; Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Anaesthesia
Most Recent Events
- 06 Dec 2023 Ahon Pharmaceutical initiates a pharmacokinetics phase I trial for Anaesthesia in China (IV) (NCT06176716)
- 11 Oct 2023 Phase-III clinical trials in Anaesthesia in China (IV) (NCT06203431)
- 05 Jul 2022 Phase-II clinical trials in Anaesthesia in China (IV) (Shanghai Fosun Pharmaceutical pipeline, October 2022)